导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.55% | 3310/4700 |
| 近一周 | -4.77% | 5111/5371 |
| 近一月 | -2.62% | 1761/5328 |
| 近一季 | -8.86% | 3367/5140 |
| 近半年 | -13.99% | 3877/4839 |
| 近一年 | 19.95% | 527/4338 |
| 近两年 | 110.83% | 520/2925 |
| 近三年 | 81.53% | 226/2229 |
| 成立以来 | 258.40% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.27% 766/4961 |
-7.65% 3787/5312 |
- - |
- - |
| 2025 | 92.97% 36/4813 |
9.40% 395/3635 |
5.33% 608/4076 |
45.43% 594/4524 |
15.15% 71/4813 |
| 2024 | 6.48% 1753/3463 |
10.79% 39/2808 |
-3.72% 1412/3014 |
10.67% 2606/3129 |
-9.81% 2953/3463 |
| 2023 | -6.31% 828/2656 |
7.26% 588/2280 |
-7.14% 1786/2385 |
-2.34% 667/2515 |
-3.68% 761/2655 |
| 2022 | -16.40% 476/2207 |
-5.66% 198/1919 |
5.37% 912/2016 |
-15.64% 1327/2113 |
-0.31% 1592/2208 |
| 2021 | 37.99% 43/1822 |
4.24% 153/1255 |
11.61% 367/1330 |
24.47% 28/1466 |
-4.71% 1492/1822 |
| 2020 | 42.42% 269/1250 |
-13.24% 923/1022 |
10.42% 765/1060 |
11.91% 412/1152 |
- - |
| 2019 | 27.67% 537/1092 |
20.45% 606/748 |
-1.89% 326/797 |
-5.77% 796/844 |
14.64% 19/912 |
| 2018 | -37.09% 595/834 |
- - |
- - |
- - |
-13.51% 538/691 |
| 2017 | 27.01% 97/714 |
- - |
- - |
- - |
- - |
| 2016 | -5.64% 179/605 |
- - |
- - |
- - |
- - |
| 2015 | -7.52% 282/575 |
- - |
- - |
- - |
- - |
| 2014 | 29.38% 169/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中信保诚中证800有色指数(LOF)A VS. 长安沪深300非周期A(740101) |